Table of Content

1. Executive Summary
   1.1. Global Intravitreal (IVT) Injectable Market Snapshot, 2024 and 2031
   1.2. Market Opportunity Assessment, 2024 - 2031, US$ Mn
   1.3. Key Market Trends
   1.4. Future Market Projections
   1.5. Premium Market Insights
   1.6. Industry Developments and Key Market Events
   1.7. PMR Analysis and Recommendations
2. Market Overview
   2.1. Market Scope and Definition
   2.2. Market Dynamics
       2.2.1. Drivers
       2.2.2. Restraints
       2.2.3. Opportunity
       2.2.4. Challenges
       2.2.5. Key Trends
   2.3. Product Lifecycle Analysis
   2.4. Intravitreal (IVT) Injectable Market: Value Chain
       2.4.1. List of Raw Material Supplier
       2.4.2. List of Manufacturers
       2.4.3. List of Distributors
       2.4.4. List of Production Methods
       2.4.5. Profitability Analysis
   2.5. Macro-Economic Factors
       2.5.1. Global Sectorial Outlook
       2.5.2. Global GDP Growth Outlook
       2.5.3. Global Parent Market Overview
   2.6. Forecast Factors - Relevance and Impact
   2.7. Covid-19 Impact Assessment
   2.8. PESTLE Analysis
   2.9. Porter Five Force’s Analysis
   2.10. Geopolitical Tensions: Market Impact
   2.11. Regulatory and Technology Landscape
3. Macro-economic Factors
   3.1. GDP Growth Outlook
   3.2. Global Healthcare Industry Outlook
   3.3. Global Aerospace & Defence Industry Overview
4. Price Trend Analysis, 2019 - 2031
   4.1. Key Highlights
   4.2. Key Factors Impacting Product Prices
   4.3. Prices By Indication /Method
   4.4. Regional Prices and Product Preferences
5. Global Intravitreal (IVT) Injectable Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   5.1. Key Highlights
       5.1.1. Market Volume (Unit) Projections
       5.1.2. Market Size and Y-o-Y Growth
       5.1.3. Absolute $ Opportunity
   5.2. Market Size (US$ Mn) Analysis and Forecast
       5.2.1. Historical Market Size Analysis, 2019-2023
       5.2.2. Current Market Size Forecast, 2024-2031
   5.3. Global Intravitreal (IVT) Injectable Market Outlook: Source
       5.3.1. Introduction / Key Findings
       5.3.2. Historical Market Size (US$ Mn) Analysis By Indication , 2019 - 2023
       5.3.3. Current Market Size (US$ Mn) Forecast By Indication , 2024 - 2031
           5.3.3.1. Macular Degeneration
           5.3.3.2. Diabetic Retinopathy
           5.3.3.3. Retinal Vein Occlusion
           5.3.3.4. Endophthalmitis
           5.3.3.5. Others
   5.4. Market Attractiveness Analysis: Indication
   5.5. Global Intravitreal (IVT) Injectable Market Outlook: Drug Class
       5.5.1. Introduction / Key Findings
       5.5.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2019 - 2023
       5.5.3. Current Market Size (US$ Mn) Forecast By Drug Class, 2024 - 2031
           5.5.3.1. Anti-VEGF
           5.5.3.2. Corticosteroids
           5.5.3.3. Antibiotics
           5.5.3.4. Antivirals
           5.5.3.5. Antifungals
   5.6. Market Attractiveness Analysis: Drug Class
6. Global Intravitreal (IVT) Injectable Market Outlook: Region
   6.1. Key Highlights
   6.2. Historical Market Size (US$ Mn) Analysis By Region, 2019 - 2023
   6.3. Current Market Size (US$ Mn) Forecast By Region, 2024 - 2031
       6.3.1. North America
       6.3.2. Europe
       6.3.3. East Asia
       6.3.4. South Asia and Oceania
       6.3.5. Latin America
       6.3.6. Middle East & Africa
   6.4. Market Attractiveness Analysis: Region
7. North America Intravitreal (IVT) Injectable Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   7.1. Key Highlights
   7.2. Pricing Analysis
   7.3. Historical Market Size (US$ Mn) Analysis By Market, 2019 - 2023
       7.3.1. By Country
       7.3.2. By Indication
       7.3.3. By Drug Class
   7.4. Current Market Size (US$ Mn) Forecast By Country, 2024 - 2031
       7.4.1. U.S.
       7.4.2. Canada
   7.5. Current Market Size (US$ Mn) Forecast By Indication , 2024 - 2031
       7.5.1. Macular Degeneration
       7.5.2. Diabetic Retinopathy
       7.5.3. Retinal Vein Occlusion
       7.5.4. Endophthalmitis
       7.5.5. Others
   7.6. Current Market Size (US$ Mn) Forecast By Drug Class, 2024 - 2031
       7.6.1. Anti-VEGF
       7.6.2. Corticosteroids
       7.6.3. Antibiotics
       7.6.4. Antivirals
       7.6.5. Antifungals
   7.7. Market Attractiveness Analysis
8. Europe Intravitreal (IVT) Injectable Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   8.1. Key Highlights
   8.2. Pricing Analysis
   8.3. Historical Market Size (US$ Mn) Analysis By Market, 2019 - 2023
       8.3.1. By Country
       8.3.2. By Indication
       8.3.3. By Drug Class
   8.4. Current Market Size (US$ Mn) Forecast By Country, 2024 - 2031
       8.4.1. Germany
       8.4.2. France
       8.4.3. U.K.
       8.4.4. Spain
       8.4.5. Russia
       8.4.6. Türkiye
       8.4.7. Rest of Europe
   8.5. Current Market Size (US$ Mn) Forecast By Indication , 2024 - 2031
       8.5.1. Macular Degeneration
       8.5.2. Diabetic Retinopathy
       8.5.3. Retinal Vein Occlusion
       8.5.4. Endophthalmitis
       8.5.5. Others
   8.6. Current Market Size (US$ Mn) Forecast By Drug Class, 2024 - 2031
       8.6.1. Anti-VEGF
       8.6.2. Corticosteroids
       8.6.3. Antibiotics
       8.6.4. Antivirals
       8.6.5. Antifungals
   8.7. Market Attractiveness Analysis
9. East Asia Intravitreal (IVT) Injectable Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   9.1. Key Highlights
   9.2. Pricing Analysis
   9.3. Historical Market Size (US$ Mn) Analysis By Market, 2019 - 2023
       9.3.1. By Country
       9.3.2. By Indication
       9.3.3. By Drug Class
   9.4. Current Market Size (US$ Mn) Forecast By Country, 2024 - 2031
       9.4.1. China
       9.4.2. Japan
       9.4.3. South Korea
   9.5. Current Market Size (US$ Mn) Forecast By Indication , 2024 - 2031
       9.5.1. Macular Degeneration
       9.5.2. Diabetic Retinopathy
       9.5.3. Retinal Vein Occlusion
       9.5.4. Endophthalmitis
       9.5.5. Others
   9.6. Current Market Size (US$ Mn) Forecast By Drug Class, 2024 - 2031
       9.6.1. Anti-VEGF
       9.6.2. Corticosteroids
       9.6.3. Antibiotics
       9.6.4. Antivirals
       9.6.5. Antifungals
   9.7. Market Attractiveness Analysis
10. South Asia & Oceania Intravitreal (IVT) Injectable Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   10.1. Key Highlights
   10.2. Pricing Analysis
   10.3. Historical Market Size (US$ Mn) Analysis By Market, 2019 - 2023
       10.3.1. By Country
       10.3.2. By Indication
       10.3.3. By Drug Class
   10.4. Current Market Size (US$ Mn) Forecast By Country, 2024 - 2031
       10.4.1. India
       10.4.2. Southeast Asia
       10.4.3. Rest of South Asia & Oceania
   10.5. Current Market Size (US$ Mn) Forecast By Indication , 2024 - 2031
       10.5.1. Macular Degeneration
       10.5.2. Diabetic Retinopathy
       10.5.3. Retinal Vein Occlusion
       10.5.4. Endophthalmitis
       10.5.5. Others
   10.6. Current Market Size (US$ Mn) Forecast By Drug Class, 2024 - 2031
       10.6.1. Anti-VEGF
       10.6.2. Corticosteroids
       10.6.3. Antibiotics
       10.6.4. Antivirals
       10.6.5. Antifungals
   10.7. Market Attractiveness Analysis
11. Latin America Intravitreal (IVT) Injectable Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   11.1. Key Highlights
   11.2. Pricing Analysis
   11.3. Historical Market Size (US$ Mn) Analysis By Market, 2019 - 2023
       11.3.1. By Country
       11.3.2. By Indication
       11.3.3. By Drug Class
   11.4. Current Market Size (US$ Mn) Forecast By Country, 2024 - 2031
       11.4.1. Brazil
       11.4.2. Mexico
       11.4.3. Rest of Latin America
   11.5. Current Market Size (US$ Mn) Forecast By Indication , 2024 - 2031
       11.5.1. Macular Degeneration
       11.5.2. Diabetic Retinopathy
       11.5.3. Retinal Vein Occlusion
       11.5.4. Endophthalmitis
       11.5.5. Others
   11.6. Current Market Size (US$ Mn) Forecast By Drug Class, 2024 - 2031
       11.6.1. Anti-VEGF
       11.6.2. Corticosteroids
       11.6.3. Antibiotics
       11.6.4. Antivirals
       11.6.5. Antifungals
   11.7. Market Attractiveness Analysis
12. Middle East & Africa Intravitreal (IVT) Injectable Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   12.1. Key Highlights
   12.2. Pricing Analysis
   12.3. Historical Market Size (US$ Mn) Analysis By Market, 2019 - 2023
       12.3.1. By Country
       12.3.2. By Indication
       12.3.3. By Drug Class
   12.4. Current Market Size (US$ Mn) Forecast By Country, 2024 - 2031
       12.4.1. GCC
       12.4.2. Egypt
       12.4.3. South Africa
       12.4.4. Northern Africa
       12.4.5. Rest of Middle East & Africa
   12.5. Current Market Size (US$ Mn) Forecast By Indication , 2024 - 2031
       12.5.1. Macular Degeneration
       12.5.2. Diabetic Retinopathy
       12.5.3. Retinal Vein Occlusion
       12.5.4. Endophthalmitis
       12.5.5. Others
   12.6. Current Market Size (US$ Mn) Forecast By Drug Class, 2024 - 2031
       12.6.1. Anti-VEGF
       12.6.2. Corticosteroids
       12.6.3. Antibiotics
       12.6.4. Antivirals
       12.6.5. Antifungals
   12.7. Market Attractiveness Analysis
13. Competition Landscape
   13.1. Market Share Analysis, 2023
   13.2. Market Structure
       13.2.1. Competition Intensity Mapping By Market
       13.2.2. Competition Dashboard
       13.2.3. Apparent Production Capacity
   13.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
       13.3.1. Regeneron Pharmaceuticals, Inc.
           13.3.1.1. Overview
           13.3.1.2. Segments and Products
           13.3.1.3. Key Financials
           13.3.1.4. Market Developments
           13.3.1.5. Market Strategy
       13.3.2. Bausch & Lomb
       13.3.3. Novartis AG
       13.3.4. Allergan
       13.3.5. Alimera Sciences
       13.3.6. ThromboGenics, Inc.
       13.3.7. Bristol-Myers Squibb Company
Note: List of companies is not exhaustive in nature. It is subject to further augmentation during course of research
14. Appendix
   14.1. Research Methodology
   14.2. Research Assumptions
   14.3. Acronyms and Abbreviations